Lars Kuepfer
Overview
Explore the profile of Lars Kuepfer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Franz M, Jairam R, Kuepfer L, Hanke N
Front Pharmacol
. 2024 Oct;
15:1418870.
PMID: 39411068
Introduction: Animal models play a vital role in pharmaceutical research and development by supporting the planning and design of later clinical studies. To improve confidence and reliability of first in...
2.
Jairam R, Franz M, Hanke N, Kuepfer L
Front Pharmacol
. 2024 Sep;
15:1427325.
PMID: 39263566
Physiologically based pharmacokinetic (PBPK) modelling is an important tool to predict drug disposition in the body. Rabbits play a pivotal role as a highly valued small animal model, particularly in...
3.
Geci R, Gadaleta D, Garcia de Lomana M, Ortega-Vallbona R, Colombo E, Serrano-Candelas E, et al.
Arch Toxicol
. 2024 May;
98(8):2659-2676.
PMID: 38722347
Physiologically based kinetic (PBK) modelling offers a mechanistic basis for predicting the pharmaco-/toxicokinetics of compounds and thereby provides critical information for integrating toxicity and exposure data to replace animal testing...
4.
Meiners F, Hinz B, Boeckmann L, Secci R, Sueto S, Kuepfer L, et al.
Sci Rep
. 2024 Mar;
14(1):6286.
PMID: 38491064
The major risk factor for chronic disease is chronological age, and age-related chronic diseases account for the majority of deaths worldwide. Targeting senescent cells that accumulate in disease-related tissues presents...
5.
Fendt R, Ghallab A, Myllys M, Hofmann U, Hassan R, Hobloss Z, et al.
Front Pharmacol
. 2023 Dec;
14:1279357.
PMID: 38053838
Liver cirrhosis is known to affect drug pharmacokinetics, but the functional assessment of the underlying pathophysiological alterations in drug metabolism is difficult. Cirrhosis in mice was induced by repeated treatment...
6.
Kister B, Viehof A, Rolle-Kampczyk U, Schwentker A, Treichel N, Jennings S, et al.
iScience
. 2023 Oct;
26(10):107922.
PMID: 37817939
Bile acid (BA) metabolism is a complex system that includes a wide variety of primary and secondary, as well as conjugated and unconjugated BAs that undergo continuous enterohepatic circulation (EHC)....
7.
Kuepfer L, Fuellen G, Stahnke T
CPT Pharmacometrics Syst Pharmacol
. 2023 Jan;
12(3):288-299.
PMID: 36708082
Good eyesight belongs to the most-valued attributes of health, and diseases of the eye are a significant healthcare burden. Case numbers are expected to further increase in the next decades...
8.
Soppert J, Brandt E, Heussen N, Barzakova E, Blank L, Kuepfer L, et al.
Clin Gastroenterol Hepatol
. 2022 Dec;
21(11):2746-2758.
PMID: 36470528
Background & Aims: Growing evidence supports a role of gut-derived metabolites in nonalcoholic fatty liver disease (NAFLD), but the relation of endotoxin levels with gut permeability and NAFLD stage remains...
9.
Collin C, Gebhardt T, Golebiewski M, Karaderi T, Hillemanns M, Khan F, et al.
J Pers Med
. 2022 Feb;
12(2).
PMID: 35207655
The future development of personalized medicine depends on a vast exchange of data from different sources, as well as harmonized integrative analysis of large-scale clinical health and sample data. Computational-modelling...
10.
Schneider A, Schneider C, Schneider K, Baier V, Schaper S, Diedrich C, et al.
Liver Int
. 2022 Jan;
42(3):640-650.
PMID: 35007409
Background & Aims: Decompensation is a hallmark of disease progression in cirrhotic patients. Early detection of a phase transition from compensated cirrhosis to decompensation would enable targeted therapeutic interventions potentially...